Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor

doi:10.4239/wjd.v12.i7.932

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9659)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

636

WORD

205

HTML

5498

Figures (1-1)

659

Sum=6998

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

336

Download

876

Sum=1212

Publishing Process of This Article

Item

Count

Browse

464

Download

985

Sum=1449

Jul 15, 2021 (publication date) through Dec 21, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

World J Diabetes. Jul 15, 2021; 12(7): 932-938
Published online Jul 15, 2021. doi: 10.4239/wjd.v12.i7.932

Open in New Tab Full Size Figure Download Figure

Figure 1 Potential benefits of sodium-glucose co-transporter-2 inhibitors in treatment of different metabolic and cardiovascular features of polycystic ovary syndrome. NAFLD: Non-alcoholic fatty liver disease; PCOS: Polycystic ovary syndrome; SGLT-2i: Sodium-glucose co-transporter-2 inhibitors; T2DM: Type 2 diabetes.

Citation: Marinkovic-Radosevic J, Cigrovski Berkovic M, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. World J Diabetes 2021; 12(7): 932-938
URL: https://www.wjgnet.com/1948-9358/full/v12/i7/932.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i7.932